Skip to main content
If you continue browsing this website, you agree to our policies:
  • Cookie Statement
  • Privacy Policy
  • Personal Data Protection Policy
Continue
x
  • Welcome to the Wits RHI eLearning Portal.
Font size: AAA
Wits RHI eLearning Portal
    ×

    Forgot your username or password?

    SearchCloseLog inClose
    1. Home
    2. Courses
    3. Shandukani Research Centre
    4. Protocols and MOPs
    MK1439-066_Data Entry Guidelines V12_02 September 2025

    MK1439-066_Data Entry Guidelines V12_02 September 2025

    Enter this course
    GS-US-380-6684_Medidata Rave eCRF Completion Guidelines Version 3.0_19 February 2025

    GS-US-380-6684_Medidata Rave eCRF Completion Guidelines Version 3.0_19 February 2025

    Enter this course
    IMPAACT 2036 Clarification Memorandum #2_26 September 2025

    IMPAACT 2036 Clarification Memorandum #2_26 September 2025

    Enter this course
    Gilead eCRF Completion Guidelines Version 3.0_Revised 24 September 2025

    Gilead eCRF Completion Guidelines Version 3.0_Revised 24 September 2025

    Enter this course
    IMPAACT 2036 MOPI Number 3_26 September 2025

    IMPAACT 2036 MOPI Number 3_26 September 2025

    Enter this course
    Gilead MOP: A Phase 2, Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Long-Acting Lenacapavir in Combination With an Optimized Background Regimen in Treatment-experienced Adolescents and Chi

    Gilead MOP: A Phase 2, Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Long-Acting Lenacapavir in Combination With an Optimized Background Regimen in Treatment-experienced Adolescents and Chi

    Enter this course
    IMPAACT 2036 eCRF Completion Guide Version 2.0.0.2_Revised 23 July 2025

    IMPAACT 2036 eCRF Completion Guide Version 2.0.0.2_Revised 23 July 2025

    Enter this course
    IMPAACT 2036 Lab Processing Chart Version 2.0_Revised 27 May 2025

    IMPAACT 2036 Lab Processing Chart Version 2.0_Revised 27 May 2025

    Enter this course
    IMPAACT 2036 Protocol Version 2.0 and MOP Version 3.0

    IMPAACT 2036 Protocol Version 2.0 and MOP Version 3.0

    Enter this course
    IMPAACT 2036 MOP: Phase I/II Study of the Safety, Tolerability, Acceptability & Pharmacokinetics of Oral & Long-Acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to

    IMPAACT 2036 MOP: Phase I/II Study of the Safety, Tolerability, Acceptability & Pharmacokinetics of Oral & Long-Acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to

    Enter this course

    Blocks

    Skip Navigation

    Navigation

    • Home

      • My courses

      • Search

      • ForumSite announcements

      • My courses

      • Courses

        • Gophelega Project

        • General

        • Implementation Science

        • Shandukani Research Centre

          • SUSARS

          • SOPs

          • Protocols and MOPs

            • MK1439-066_ Data Entry Guidelines_V12

            • GS-US-380-6684_ eCRF_V3.0

            • IMPAACT_ CM2

            • Gilead_ eCRF_V3.0

            • IMPAACT_ MOPI_#3

            • Shan_Gilead_MOP_V1

            • IMPAACT_ eCRF_V2.0.0.2

            • IMPAACT_ LPC_V2.0

            • IMPAACT_Protocol and MOP_V2.0_V3.0

            • Shan_IMPAACT2036_MOP_V3

          • General

        • Wits RHI Research Team

        • Len4PrEP SSPs Training

    • Should you have any navigation queries, please email wrhitraining@academicadvance.co.za.

    Academic Advance 2020. All rights reserved.

    Hide sidebars